- About us
- Clinical trials
- News & Publications
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. Our robust pipeline includes a next-generation PD-1-inhibiting cytokine, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). We are building a pipeline of oncology programs by pursuing promising early-stage candidates backed by strong science through strategic licensing, M&A and in-house discovery efforts. Our company has established the key capabilities required for research, preclinical and clinical development, commercial planning, and market access, with the goal to rapidly advance the programs in our portfolio through clinical development towards commercialization.
SOTIO is developing the next generation of potent immunotherapies for patients with cancer. To achieve this goal, we intend to acquire therapeutic oncology assets that are at advanced preclinical or clinical stages to include in our portfolio. We are looking for differentiated drugs of varying modalities (small molecules, biologics, cell therapies, etc.) that have the potential to make a real difference in patients suffering from cancer.
SOTIO has research laboratories located in Prague (Czech Republic) and offices in Prague, Boston, MA and Basel (Switzerland). The company collaborates with leading research teams and hospitals in the US and Europe. SOTIO has also direct access to the GMP manufacturing capabilities in Prague.